摘要
目的：观察紫杉醇联合顺铂治疗晚期非小细胞肺癌的近期疗效厦不良反应。方法：国产紫杉醇85mg／m^2静脉滴注第1，8，15d用药；顺铂20mg／m^2静脉滴注1～5d用药。28d为1周期，连用3周期。结果：30例可评价疗效总有效率（CR＋PR）53．3％，其中CR1例为初治患者，有效率60％，复治患者有效率33．3％。不良反应为骨髓抑制、脱发、关节肌肉疼痛、消化道反应，其他不良反应轻微均可耐受。结论：紫杉醇联合顺铂治疗晚期非小细胞肺癌可获得较好疗效且不良反应可耐受。
Objective To evaluate the results of paclitaxel plus cisplatin in the treatment of advanced non-small cell lung cancer. Methods Thirty patients with advanced non-small cell lung cancer received paclitaxel 85 mg/m^2by intravenous infusion on day 1, 8,15 and cisplatin 20 mg/m^2 by intravenous infusion on day 1 to 5. The treatment was repeated every 28 days, up to 3 courses. Results Of all cases, 1 got complete response（3.3%）, 15 got partial response（50%）, with an overall rate of 53.3%. The main toxicities were myelosuppression, nausea and vomiting, and other side effects were mild. Conclusion A high response rate can be obtained in advanced non-small cell lung cancer by paclitaxel plus cisplatin. Paclitaxel is a promising antitumor agent with tolerable toxicity
出处
《实用诊断与治疗杂志》
2006年第2期120-121,共2页
Journal of Practical Diagnosis and Therapy
